Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1999 2
2001 1
2008 1
2009 2
2010 1
2012 1
2018 1
2019 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group. D'Haens G, et al. N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. N Engl J Med. 2023. PMID: 37379135 Clinical Trial.
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, Kanke K, Kobayashi K, Hirai F, Watanabe K, Mizusawa H, Kishida S, Miura Y, Ohta A, Kajioka T, Hibi T; AJM300 Study Group. Matsuoka K, et al. Lancet Gastroenterol Hepatol. 2022 Jul;7(7):648-657. doi: 10.1016/S2468-1253(22)00022-X. Epub 2022 Mar 30. Lancet Gastroenterol Hepatol. 2022. PMID: 35366419 Clinical Trial.
Colorectal neuroendocrine carcinoma: A case report and review of the literature.
Yoshida T, Kamimura K, Hosaka K, Doumori K, Oka H, Sato A, Fukuhara Y, Watanabe S, Sato T, Yoshikawa A, Tomidokoro T, Terai S. Yoshida T, et al. Among authors: tomidokoro t. World J Clin Cases. 2019 Jul 26;7(14):1865-1875. doi: 10.12998/wjcc.v7.i14.1865. World J Clin Cases. 2019. PMID: 31417933 Free PMC article. Review.
Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
Inada S, Tomidokoro T, Fukunari H, Sato T, Hatano T, Nishimura A, Kawauchi Y, Nikkuni K, Shimizu T, Sato T, Yanagi M, Takahashi S, Yoshida H, Sugita M, Hayashi T. Inada S, et al. Among authors: tomidokoro t. Cancer Chemother Pharmacol. 2009 Jan;63(2):267-73. doi: 10.1007/s00280-008-0736-4. Epub 2008 Apr 1. Cancer Chemother Pharmacol. 2009. PMID: 18379784 Clinical Trial.
Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study.
Koizumi W, Akiya T, Sato A, Sakuyama T, Sasaki E, Tomidokoro T, Hamada T, Fujimori M, Kikuchi Y, Shimada K, Mine T, Yamaguchi K, Sasaki T, Kurihara M. Koizumi W, et al. Among authors: tomidokoro t. Cancer Chemother Pharmacol. 2010 May;65(6):1093-9. doi: 10.1007/s00280-009-1114-6. Epub 2009 Aug 30. Cancer Chemother Pharmacol. 2010. PMID: 19727730 Clinical Trial.
12 results